Two Major Genetics Studies, One Powerful Message: Fibromyalgia Is Real, Biological, and Rooted in Your Nervous System
Back in December, I wrote about a landmark genetics study that changed how the scientific world understands fibromyalgia. That study analyzed 2.5 million people and found real, measurable genetic roots for our condition, which was additional proof that fibromyalgia isn't "in our head."
I didn't expect to be back here so soon with more proof. But in July 2026, a second major genetics study from Yale, published in Nature Communications, added a whole new layer to the picture, so I have rewritten this post to include these new findings.
Let's walk through what each study found, where they agree, where there is something new, and what it all means for how you understand your own body.
New to FibroSoul? Start with the free 7-Day Gentle Reset, a practical, science-informed guide to supporting your body if you have fibromyalgia. Download it free →
Browse by topic: [Research & Science] [Medications & Treatment] [Nutrition & Diet] [Pain & Symptoms] [Women's Health]
Study One: The 2025 Study with 2.5 Million People
Led by researchers at Fred Hutch Cancer Center in Seattle, the University of Toronto, and the University of Helsinki, this study analyzed genetic data from 2.5 million adults across the US, UK, Finland, Estonia, Denmark, and Iceland — the largest fibromyalgia genetics study ever conducted at the time.
The headline findings:
26 genetic variants were linked to fibromyalgia risk.
The strongest of these variants sits in a gene called HTT, which is the same geneinvolved in Huntington's disease, with a related variant pointing to a receptor called GPR52, which is already being studied as a drug target for Huntington's. This doesn't mean fibromyalgia and Huntington's are the same thing, but it does point researchers toward specific biological targets that could one day lead to new treatments/
Genes near fibromyalgia risk variants were far more active in nervous system cells than in other cell types, which is strong evidence that fibromyalgia is fundamentally a neurological condition, not an autoimmune one.
Fibromyalgia shares genetic overlap with low back pain, IBS, and PTSD. Do you find this is true for you?
Although men and women share the same genetic risk architecture, fibromyalgia is more commonly diagnosed in women, likely due to hormonal, environmental, or diagnostic factors, not different genes.
Genetics alone don't determine who develops fibromyalgia. Most people likely need a second trigger, like an injury or an inflammatory condition, layered on top of genetic risk.
Study Two: Yale's 2026 Study with 1.7 Million People
The Yale study, led by Dr. Uri Bright and Dr. Joel Gelernter and published on July 28, 2026, took a different — and, in some ways, complementary — approach. Instead of one massive combined dataset, the team drew on several major biobanks (All of Us, the Million Veteran Program, UK Biobank, and FinnGen). It included 1.7 million participants, including about 85,000 people with fibromyalgia, spanning European, African, and Latin American ancestries, which is a meaningful step toward genetics research that reflects more of us.
Using a statistical method that combines fibromyalgia data with broader pain research (called multi-trait GWAS analysis), the Yale team identified 45 independent genomic risk locations in total: 10 in people of European ancestry, 1 in African ancestry, and 12 that held up across ancestries.
Here's where it gets interesting:
The strongest genetic correlation with fibromyalgia was chronic pain itself, followed closely by migraine.
When the researchers modeled how fibromyalgia's genetics relate to other conditions, they found shared architecture with chronic pain, migraine, endometriosis, autoimmune response, insomnia, and physical activity levels.
Despite real correlations with depression, PTSD, ADHD, and suicidality, the researchers concluded fibromyalgia is better understood as a pain- and autoimmune-related trait than a psychiatric one.
They also found a moderate genetic link between fibromyalgia and both opioid use disorder and cannabis use disorder, which is relevant, given how often one or both substances come up in pain management conversations.
As in the first study, fibromyalgia is diagnosed far more in women (75% of cases), but the underlying genetic architecture is the same across sexes.
Where the Studies Agree and Where They Diverge
I know that's a lot of findings, so let's put them side by side, because the comparison itself is illuminating.
They agree on the big picture: Fibromyalgia has a real, measurable genetic basis. It is not imagined, not purely psychological, and not simply a byproduct of anxiety or depression. Both studies also independently confirm that the genetics don't differ by sex, so whatever explains why fibromyalgia shows up more in women, it isn't your genes.
They diverge on emphasis. The Fred Hutch/Toronto/Helsinki study leans hard into a neurological story: fibromyalgia genes are most active in nervous system tissue, which points toward the brain and nerves as the primary driver. The Yale study, using its genomic modeling, leans toward a pain-and-immune story: fibromyalgia's genetic architecture overlaps more with autoimmune-related traits than psychiatric ones, and its single strongest correlation is with chronic pain broadly.
I don't think these two conclusions actually contradict each other — I think they're describing different angles of the same elephant. Fibromyalgia likely involves both a nervous system that's become more sensitized and immune-related processes that interact with it. That fits with what many of us have felt in our bodies for years: this condition doesn't stay in one lane.
One genuinely new piece: The Yale study is the first of these two to flag a genetic connection to opioid and cannabis use disorder risk. That's not a judgment on anyone's pain management choices — it's a data point worth having if you're weighing treatment options with your doctor.
What Stays True in Both Studies
However you slice it, both of these studies land in the same place:
Fibromyalgia has identifiable genetic underpinnings.
It behaves like a condition of the nervous system and pain-processing pathways, closely related to other pain and sensory conditions.
Genetics load the gun, but they don't pull the trigger alone: environment, life events, and other health conditions appear to determine whether fibromyalgia actually develops.
Because environment matters this much, the pathways involved are modifiable. This is great news. This means we can make changes to improve our symptoms.
That last point is the one I keep coming back to. Although we can't change our genes, we can change the environment those genes operate in, including how we sleep, move, eat, manage stress, and support our nervous systems day to day. Two studies, using different data and different methods, both arrived at a version of that same conclusion.
What This Means for You
Fibromyalgia is biological. It's rooted in your nervous system and pain pathways. And a growing body of genetic evidence from two of the largest studies ever conducted confirms it.
Researchers are still working out exactly how genes, environment, and other conditions interact to produce fibromyalgia in one person and not another. But every study like this narrows the gap between "we don't understand this" and "we do," and that gap closing is good news for all of us.
If you're looking for science-backed support alongside lived experience, take a look at our FAQ page. You don't have to make sense of any of this alone.
Your body is not broken. It is communicating. And the science is finally starting to listen.
Sources: Kerrebijn I, Bjornsdottir G, Arbabi K, et al. The genetic architecture of fibromyalgia across 2.5 million individuals. Nat Med. 2026.
Bright U, et al. Genetic architecture of fibromyalgia across multiple biobanks and ancestries. Nature Communications. 2026 (Yale University).